India Pharma Outlook Team | Wednesday, 15 October 2025
Suraksha Diagnostic, a prominent diagnostic chain located in Eastern India, held an informative scientific session on Advances in Genetics and Reproductive Health.
The attendees heard from highly regarded experts from around the globe on the latest research and developments in Prenatal, Postnatal, and Preimplantation Genetic Testing (PGT).
Prenatal Genetic Testing which was a primary focus during the session was led by Dr. Michael Richardson, Senior Director, APAC, Yourgene Health, on Non-Invasive Prenatal Testing (NIPT) and confirmatory testing and Dr. Xin Yue Chan, Product Specialist, Thermo Fisher Scientific, on CytoMicroArray applications in genetic analysis. Alain Rico, Senior Product Manager, Thermo Fisher Scientific, presented on PGT-A, and its changing role in IVF success rates.
Also Read: How to Bridge the Healthcare Gap in Emerging Markets with MedTech
Dr. Somnath Chatterjee, chairman & joint managing director, Suraksha Clinic & Diagnostics, said: "Reproductive genomics has truly transformed the landscape of maternal and fetal healthcare. Suraksha Clinic and Diagnostics serves as a one-stop technology centre, combining advanced genomic tools with expert cytogenetic interpretation to ensure the most accurate diagnosis and better reproductive health outcomes."
India has about 25 million births a year, and diagnosing genetic abnormalities such as Down syndrome (Trisomy 21), Patau syndrome (Trisomy 13), and Edwards syndrome (Trisomy 18) early on is important. With families giving birth to fewer children as the Total Fertility Rate (1.9) declines, the interest in NIPT and Microarray Testing has increased to enable safer pregnancies and better outcomes.
The Non-Invasive Prenatal Testing market in India was valued at $0.40 billion in 2024 and is expected to grow to $1.20 billion by 2033 as technology evolves, knowledge increases, and maternal age becomes higher. Accordingly, NIPT prices will be approximately ?10,000–30,000, while PGT-A will be about ?12,000–27,000 per embryo. Genetic testing will continue to change the landscape of reproductive health for the better in India.
